International Circulation: Can you give us any indications of what you expect the trial to reveal?
　　《国际循环》：您期待这项试验会揭示出什么结果，能否给我们一些提示？
　　Prof Libby: As I pointed out at the outset of the interview， inflammation is very redundant and there are many different arms. What the most important target is， I don’t have any way of knowing. We can kill a lot of mice in your laboratory and not answer that question; you need to do the human experiments. There have been maybe a hundred anti-hypertensive trials and maybe fifty anti-lipid trials， but this is the first anti-inflammation trial. It will probably take us a number of explorations to find just the right target. There are a lot of arrows that point to interleukin-1 beta as an attractive target so Dr Paul Ridker， who is the principle investigator for both JUPITER and CANTOS， is devoting a lot of our professional effort to try and test that hypothesis. It is probably going to take a suite of studies to explore that hypothesis that a direct anti-inflammatory agent can reduce cardiovascular events.
　　Prof Libby：正如我在采访开始时指出的，炎症广泛存在，有许多不同类别。最重要的靶点是什么？我们对此一无所知。我们可以在实验室中杀掉大量的小鼠，但不能回答上述问题，必须进行人体实验。可能已经有了100项抗高血压试验，有了50项降脂试验，但这是第一项抗炎试验。它可能在寻找正确靶点的征途中带给我们一些探索性发现。有许多发现指向白介素-1β，这是一个很有吸引力的靶点，因此JUPITER和CANTOS试验的首席研究者Paul Ridker博士正在致力于验证这一假说。这有可能带动更多的研究去探索这一假设：一种直接抗炎的药物可能降低心血管事件。
　　International Circulation: You said that pathways were redundant. Does that imply that inhibiting one pathway would not be enough?
　　《国际循环》：您提到存在许多炎症旁路，那是否意味着抑制一个旁路是不够的？
　　Prof Libby: Yes. It may be that if you inhibit some pathways， you are going to deter host defenses which will make people susceptible to infections or reduce their tumor surveillance. With the anti-TNF strategies there are， in some cases， evidence for increased lymphoma risk. We have to be careful. We are looking for the ‘sweet spot’ in anti-inflammatory therapy.
　　Prof Libby：是的。当抑制一些旁路时，可能我们会同时抑制了宿主的免疫防御机制，使其易于感染或肿瘤监视能力下降。如有证据显示，一些病例在使用抗TNF策略后，发生淋巴瘤的风险升高。我们必须保持谨慎，我们在寻求抗炎疗法的“最佳平衡点“。